Drug intelligence / Profile preview

BBV152A

Development stage: Unknown
Lead developer: Bharat Biotech
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**BBV152A** is an investigational whole-virion, beta-propiolactone-inactivated SARS-CoV-2 vaccine formulation developed by Bharat Biotech with the Indian Council of Medical Research and the National Institute of Virology. It contains 3 micrograms of inactivated SARS-CoV-2 strain NIV-2020-770 antigen produced in Vero cells and adjuvanted with Algel-IMDG, an aluminum hydroxide gel formulation containing an imidazoquinoline TLR7/8 agonist. BBV152A was evaluated in phase 1 and phase 2 studies for prevention of COVID-19. It is distinct from the marketed BBV152 formulation sold as Covaxin, which used the 6 microgram Algel-IMDG formulation.

Targets

TLR8 (Toll-like receptor 8)TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on BBV152A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BBV152A.

Explore the full profile